Matthew Frosch, MD, PhD
Adam Boxer, MD
Adam L. Boxer, MD, PhD is the Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF). He co-chairs the ACTC Non-Alzheimer’s Dementia Committee. At UCSF, he directs the Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center. Dr. Boxer’s research is focused on developing new treatments and biomarkers for neurodegenerative diseases, particularly those involving tau and TDP-43. He is the Principal Investigator of the Advancing Research and Treatment for FTLD (ARTFL) Rare Disease Clinical Research Consortium, a collaborative project funded by the National Institutes of Health to create an 18 center North American research network to support the development of new therapies for FTLD. He also leads the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI), a multicenter, longitudinal tau PET and biomarker study focused on PSP and CBD. He has been the PI for a variety of multicenter, randomized, placebo controlled clinical trials in FTLD spectrum disorders, including memantine for FTLD, davunetide for PSP, TPI-287 for primary and secondary tauopathies, and salsalate for PSP. He co-chairs the FTLD Treatment Study Group (FTSG) and the PSP Research Roundtable, academic-industry collaborative groups working to speed the development of new therapies for FTLD, CBD and PSP.
Jason Karlawish, MD
Jason Karlawish is a Professor of Medicine, Medical Ethics and Health Policy, and Neurology at Penn and cares for patients at the Penn Memory Center (www.pennmemorycenter.org), which he co-directs. He leads the ACTC Ethics Committee, is a member of the Recruitment and Retention Core and the Steering Committee. At Penn, he leads the Outreach and Recruitment Core and Research Education Component of the ADRC. His research focuses on issues at the intersections of bioethics, aging and the neurosciences. He leads the Penn Program for Precision Medicine for the Brain (P3MB). P3MB developed standards for Alzheimer’s disease biomarker disclosure and investigates the clinical impacts of this knowledge on persons and their families. He has investigated the development and translation of Alzheimer’s disease treatments and biomarker-based diagnostics, informed consent, quality of life, research and treatment decision making, and voting by persons with cognitive impairment and residents of long term care facilities. P3MB developed the amyloid imaging disclosure process and the SOKRATES Study, originally used in the A4 Study, these have become a template for assuring the safe disclosure of Alzheimer’s disease genes and biomarkers and assessing their impact on persons and their families.
Joshua Grill, PhD
Joshua D. Grill, PhD, is an Associate Professor in the Departments of Psychiatry & Human Behavior and Neurobiology & Behavior at the University of California, Irvine (UCI). He is the Director of the Institute for Memory Impairments and Neurological Disorders (UCI MIND) and the Associate Director of the UCI Alzheimer’s Disease Research Center. He also directs its Outreach, Recruitment, and Engagement Core for the UCI ADRC and is the leader of the Accrual and Retention Consult Service for the UCI Institute for Clinical and Translational Science (ICTS). Dr. Grill serves in several roles for ACTC. He is co-leader of the Recruitment, Engagement, and Retention Unit as well as the Internal Ethics Committee. He also serves on the Executive and IDEA-CT Committees. Dr. Grill’s independent research is focused on clinical trial design, recruitment and retention, and research ethics across the spectrum of Alzheimer’s disease.